Landos Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 21.94 million compared to USD 39.28 million a year ago. Basic loss per share from continuing operations was USD 3.5 compared to USD 9.76 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.93 USD | +0.58% | +2.05% | +526.50% |
May. 24 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+526.50% | 71.68M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023